Biosimilars Compounding Pharmaceutical Companies 
STAT
NOVEMBER 18, 2022
… Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. Or you may want to take stock of your life. Well, whatever you do, have a grand time.
Express Pharma
JUNE 28, 2024
The osteoporosis market, the prevailing metabolic bone disorder globally, which is characterised by reduced bone mineral density and increased fracture risk, is set to experience a compound annual growth rate (CAGR) of 5.4 per cent across the seven major markets (7MM*) from $10.5 billion in 2023 to $17.9 billion in 2033, forecasts GlobalData.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Pathway
SEPTEMBER 14, 2022
is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Company Name: Dr. Reddy’s Laboratories Ltd.-Walk-In Job Description.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 This is due to these companies looking to meet to the varied needs of pharmaceutical developers, according to the authors.
Express Pharma
OCTOBER 16, 2024
The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 per cent, is projected to reach $2.5 billion by 2030 (2). per cent, hitting $44.63 billion by 2029 (3).
European Pharmaceutical Review
NOVEMBER 25, 2024
The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3
pharmaphorum
DECEMBER 2, 2020
It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.
Expert insights. Personalized for you.
177 
Let's personalize your content